Install
- 117articles · 30d
- 23+ hour agolatest article
- Aug 15, 2026earliest in window
- 92%with images
- 355avg words
- Health & Wellness 99
- Medical 98
- Health 67
- Science & Technology 27
- Economy, Business & Finance 22
- Finance & Business 12
- Business & Industrial 10
- News 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Mitapivat Just Rewrote the Treatment Floor for Transfusion-Dependent Thalassaemia, Here’s What the ENERGIZE-T Data Actually Mean
23+ hour, 50+ min ago (861+ words) The Clinical Trial Vanguard Mitapivat Just Rewrote the Treatment Floor for Transfusion-Dependent Thalassaemia, Here’s What the ENERGIZE-T Data Actually Mean Picture the patient record that has defined thalassaemia care for decades: a transfusion schedule, printed or scrolling across a clinic…...
When the ER Is Not an Option: Milestone’s CMO on Bringing AFib Rate Control Home
3+ day, 22+ hour ago (418+ words) The FDA approval of etripamil for PSVT occurred in December, 2025. Investigation about a potential role of etripamil in highly symptomatic AFib, The ReVeRA-Phase 3, trial is another test: can this self-administered nasal spray put an all-too-frequent emergency department problem back in…...
Seismic Pharmaceuticals Enrolls First Patient in Phase 3 Trial of Istaroxime for Cardiogenic Shock
4+ day, 39+ min ago (386+ words) The Clinical Trial Vanguard Seismic Pharmaceuticals Enrolls First Patient in Phase 3 Trial of Istaroxime for Cardiogenic Shock Cardiogenic shock kills roughly half the patients it reaches in the ICU, a mortality burden that has persisted for decades without a single…...
Ascendis to Present Navepegritide Infant Trial Data at ESPE 2026
6+ day, 43+ min ago (347+ words) The Clinical Trial Vanguard Ascendis to Present Navepegritide Infant Trial Data at ESPE 2026 Sentinel cohort data from a pivotal infant trial rarely reach a major congress podium before the broader enrollment is complete, which makes Ascendis Pharma’s slot at ESPE…...
Clover’s RSV-hMPV Vaccine Shows Antibody Rises in Phase 2 Trial
1+ week, 44+ min ago (442+ words) The Clinical Trial Vanguard Clover’s RSV-hMPV Vaccine Shows Antibody Rises in Phase 2 Trial More than half of American adults 75 and older have already received one of the approved RSV vaccines, which creates an awkward problem for any late-entrant vaccine: the…...
FDA Guidance Expands Cancer Trial Eligibility, Reshaping Feasibility Models
1+ week, 1+ day ago (383+ words) The Clinical Trial Vanguard FDA Guidance Expands Cancer Trial Eligibility, Reshaping Feasibility Models Forty percent of Phase III cancer trials explicitly barred patients with an ECOG performance status of 2 or higher, and among trials that allowed those patients, they made…...
Nature Medicine’s 38,753-Patient HF Synthesis Signals a Replicable Model for RWE-Driven Label Expansion Without New RCTs
1+ week, 5+ day ago (806+ words) The Clinical Trial Vanguard Nature Medicine’s 38,753-Patient HF Synthesis Signals a Replicable Model for RWE-Driven Label Expansion Without New RCTs On July 14, 2026, Nature Medicine published a cross-trial synthesis examining short-term effects of combination heart failure therapies on blood pressure, kidney…...
Cumberland Seeks FDA Action on Ifetroban DMD Data Before Extension Study Complete
2+ week, 2+ day ago (395+ words) The Clinical Trial Vanguard Cumberland Seeks FDA Action on Ifetroban DMD Data Before Extension Study Complete Cumberland Pharmaceuticals is asking the FDA to act on data it has not yet fully made public. The 8-K filed this week discloses that…...
FDA Clears IND for EOM613 Trial in Cancer Cachexia Patients
2+ week, 6+ day ago (214+ words) BreakBio Enters Clinic for Personalized Cancer Vaccine The Clinical Trial Vanguard BreakBio Enters Clinic for Personalized Cancer Vaccine Personalized cancer vaccines just posted their biggest clinical proof point yet: the Moderna-Merck Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met…...
Upadacitinib’s Phase 3 Vitiligo Data Just Redrew the Regulatory Map for JAK Inhibitors in Dermatology
3+ week, 4+ day ago (795+ words) The Clinical Trial Vanguard Upadacitinib’s Phase 3 Vitiligo Data Just Redrew the Regulatory Map for JAK Inhibitors in Dermatology Picture the moment a principal investigator at one of the 90 Viti-Up sites opens the unblinding envelope in late 2024. Her patient cohort includes…...